Literature DB >> 21960778

Infliximab for ulcerative colitis induction of remission and maintenance therapy.

Stephen J Bickston1.   

Abstract

Entities:  

Year:  2007        PMID: 21960778      PMCID: PMC3096120     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  3 in total

1.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

3.  Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.

Authors:  B E Sands; M A Blank; R H Diamond; J P Barrett; S J Van Deventer
Journal:  Aliment Pharmacol Ther       Date:  2006-04-15       Impact factor: 8.171

  3 in total
  1 in total

1.  Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis.

Authors:  Giovanna Casili; Marika Cordaro; Daniela Impellizzeri; Giuseppe Bruschetta; Irene Paterniti; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  J Crohns Colitis       Date:  2015-12-21       Impact factor: 9.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.